Jump to content

Harrison Stafford

Legacy Members
  • Posts

    2873
  • Joined

  • Last visited

Everything posted by Harrison Stafford

  1. You forgot to mention all the Ranger fans selling concessions who are on prison work release programs
  2. As a rule, I don’t go to the threads of pro teams of which I’m not a fan and talk trash. Having said that, this season, >this< thread was started by a Rangers fan who must be at a level of torment and self-punishment that he would expose himself like an open wound to ‘Stros fans. You lob a softball right over the middle of the plate and what would you have Astros fans do? Good Lord, man. This IS surly.
  3. It's 2022 and the Rangers have already assumed the position.
  4. ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ Business Wire4:15 PM Eastern Daylight Time Apr 01, 2022 ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has achieved a major milestone with over 80 subjects in the QUILT-3.032 study completing at least 12 months of follow-up as of January 14, 2022. All data for QUILT-3.032, which is studying VesAnktiva™ plus BCG in subjects with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS), have been locked and analyzed. The results continue to demonstrate a clinically meaningful benefit that is sustained. The BLA has been compiled and, following final quality review, is expected to be submitted to the U.S. Food and Drug Administration (FDA) this month. The FDA granted Fast Track Designation to the pivotal trial based on Phase I data. In December 2019, the FDA granted ImmunityBio Breakthrough Therapy Designation (BTD) based on interim Phase 2 data indicating the primary endpoint of the trial was already met. “We are excited to announce that the comprehensive compilation of our BLA is essentially written,” said Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific and Medical Officer at ImmunityBio. “With 71% of the participants in this study having a complete response and a median duration of response of 26.6 months, we believe we have a clinically meaningful therapeutic alternative for patients suffering from NMIBC in which the only option remaining is total cystectomy.” So, IBRX will submit their bladder cancer drug for FDA approval this month. Anytime IBRX announces anything that can be perceived as positive news the stock goes down
  5. I would go medieval on their asses.
  6. IBRX and EOSE both look to be turning up (price momentum oscillator turned up). The PMO for UUUU has turned down. Having said that, Putin will probably announce in the near future that he’s banning uranium exports and uranium stocks will soar.
  7. I don’t have anything against either team. Just hoping for a good game.
  8. From 1968 to 1972, the Moody Blues released six albums and there wasn’t a stinker in the whole lot: In Search of The Lost Chord To Our Children’s Children’s Children On The Threshold of a Dream A Question of Balance Every Good Boy Deserves Favour (EGBBF…the notes on the treble clef) Seventh Sojourn I didn’t include Days of Future Passed released in 1967 because the tune Nights in White Satin….never reaching the end….was 7 excruciating minutes of never reaching the end for me. And the song is Nights in White Satin and not Knights in White Satin.
  9. The Doors: The Doors, Strange Days, Waiting for the Sun Jethro Tull: Benefit, Aqualung, Thick As A Brick Spirit: Spirit, The Family That Plays Together, Clear, Twelve Dreams of Dr. Sardonicus (List of 4 as Spirit’s first four albums were all money)
  10. Nice trade. No one ever went broke taking a profit. If EOSE rebounds to $6, I’ll sell and look like a genius. If it retraces to the low 3’s, I’ll simply hold my position as I believe the company has a great future and the stock will revisit $6 in the next few months. Re: UUUU, the ppo has turned down and the pmo is about to do the same. 20 day ema is at $9.10. If it fails, the 50 day EMA is at $8.30. If that fails, the 200 day is at $7.26. So, the opportunity to take a trading position in UUUU sub $8 is a real possibility. Am continuing to hold 25,000 shares of UUUU with a cost basis of $5.28 as a long term position
  11. EOSE has support at 4 and again at 3.80. If those hold, then, this is a corrective move and 6 is still a reasonable upside target. If they fail, it could retrace all the way back to 3-3.20. Holding 11,500 shares of EOSE @ 3.10. No guts, no glory.
  12. Putin got some really bad intel. Of course, if you don’t tell him what he wants to hear, that retirement home on the Black Sea becomes a bed in the Hotel Gulag.
  13. F For a very weak beer, it’s best in class.
  14. EOSE +.42 to $4.48. If it can close above here, we should move to $6.
  15. https://www.zerohedge.com/markets/uranium-stocks-soar-after-russia-says-considering-ban-uranium-exports This is what’s driving uranium stocks today.
  16. UUUU +.64 to 10.34. It failed right at 10.50 a week ago. Needs to break through that price with volume.
  17. Sounds like small change got rained on
  18. The Bengals lost by 3 points in the Super Bowl. Being the Bengals ain’t so bad.
  19. If you’d set me up differently, I coulda drained a three.
  20. He doesn’t care about winning. That’s why he’s going to Cleveland.
  21. EOSE gets north of $4.40 and we should have a run to $6.
×
×
  • Create New...